Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CODX Co-Diagnostics Inc
- Stocks
- Healthcare
- NASDAQ: CODX
Price (delayed)
$0.3552
Market cap
$11.93M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.24
Enterprise value
$11.14M
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a state-of-the-art diagnostics technology. The Company's technology is utilized for tests that are designed using
Highlights
Co-Diagnostics's gross margin has surged by 93% YoY and by 51% QoQ
The company's debt fell by 28% YoY and by 9% QoQ
The company's gross profit fell by 19% QoQ but it rose by 11% YoY
CODX's EPS is up by 10% since the previous quarter but it is down by 3.3% year-on-year
Co-Diagnostics's quick ratio has shrunk by 60% YoY and by 38% QoQ
The revenue has contracted by 47% from the previous quarter and by 43% YoY
Key stats
What are the main financial stats of CODX
Market
Valuations
Earnings
Shares outstanding
33.57M
Market cap
$11.93M
Enterprise value
$11.14M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.21
Price to sales (P/S)
2.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.85
Revenue
$3.92M
Gross profit
$2.92M
Operating income
-$40.08M
Net income
-$37.64M
EBIT
-$37.58M
EBITDA
-$36.19M
Free cash flow
-$29.9M
Per share
Balance sheet
Liquidity
EPS
-$1.24
EPS diluted
-$1.24
Free cash flow per share
-$0.99
Book value per share
$1.7
Revenue per share
$0.13
TBVPS
$1.25
Total assets
$64M
Total liabilities
$9.69M
Debt
$2.15M
Equity
$54.31M
Working capital
$24.98M
Debt to equity
0.04
Current ratio
4.41
Quick ratio
4.08
Net debt/EBITDA
0.02
Margins
Efficiency
Dividend
EBITDA margin
-924.4%
Gross margin
74.5%
Net margin
-961.4%
Operating margin
-1,023.7%
Return on assets
-49.6%
Return on equity
-56%
Return on invested capital
-111.8%
Return on capital employed
-66.3%
Return on sales
-959.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CODX stock price
How has the Co-Diagnostics stock price performed over time
Intraday
1.49%
1 week
-2.66%
1 month
18.64%
1 year
-70.89%
YTD
-52.64%
QTD
14.73%
Financial performance
How have Co-Diagnostics's revenue and profit performed over time
Revenue
$3.92M
Gross profit
$2.92M
Operating income
-$40.08M
Net income
-$37.64M
Gross margin
74.5%
Net margin
-961.4%
Co-Diagnostics's gross margin has surged by 93% YoY and by 51% QoQ
Co-Diagnostics's operating margin has plunged by 87% from the previous quarter and by 63% YoY
The company's net margin has shrunk by 85% YoY and by 70% QoQ
The revenue has contracted by 47% from the previous quarter and by 43% YoY
Price vs fundamentals
How does CODX's price correlate with its fundamentals
Growth
What is Co-Diagnostics's growth rate over time
Valuation
What is Co-Diagnostics stock price valuation
P/E
N/A
P/B
0.21
P/S
2.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.85
CODX's EPS is up by 10% since the previous quarter but it is down by 3.3% year-on-year
The P/B is 91% below the 5-year quarterly average of 2.4 and 58% below the last 4 quarters average of 0.5
The equity has declined by 37% year-on-year and by 15% since the previous quarter
The revenue has contracted by 47% from the previous quarter and by 43% YoY
The P/S is 45% below the last 4 quarters average of 5.0 and 43% below the 5-year quarterly average of 4.8
Efficiency
How efficient is Co-Diagnostics business performance
CODX's return on invested capital has dropped by 100% year-on-year and by 17% since the previous quarter
CODX's return on sales has dropped by 88% since the previous quarter and by 72% year-on-year
CODX's return on equity has dropped by 58% year-on-year and by 2% since the previous quarter
The ROA has plunged by 52% YoY
Dividends
What is CODX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CODX.
Financial health
How did Co-Diagnostics financials performed over time
Co-Diagnostics's quick ratio has shrunk by 60% YoY and by 38% QoQ
The current ratio has plunged by 59% YoY and by 36% from the previous quarter
The company's debt is 96% lower than its equity
The equity has declined by 37% year-on-year and by 15% since the previous quarter
The debt to equity is up by 33% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.